Synaffix expands ADC deal from 2022 with MacroGenics

The Dutch biotech Synaffix, which has been active in the deal space out of the gate in 2023, is building on a deal it made with MacroGenics last year.

Synaffix announced Tuesday it has expanded an agreement with the biotech MacroGenics to license out its antibody conjugation platform, called GlycoConnect,...

Click to view original post